Adult Growth Hormone Deficiency Clinical Trial
Official title:
Growth Hormone Replacement Therapy in Veterans With Gulf War Illness and Adult Growth Hormone Deficiency
The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). The main questions the study aims to answer are: 1. Is growth hormone effective at reducing fat in the trunk of the body and symptoms of GWI among veterans with GWI and growth hormone deficiency? 2. Do the results of the study suggest there is merit in pursuing a larger trial to examine the efficacy of growth hormone as a treatment for growth hormone deficiency among veterans with Gulf War Illness? To determine eligibility for the study, veterans will be asked to complete several assessments including questionnaires, blood tests, and a scan of the brain. Participants who qualify for the study will receive recombinant human growth hormone for 6-months. A body composition scan will be performed at Day1, Day 90, and Day 180 of the intervention. Questionnaires and cognitive tests will also be collected before and after the trial.
Veterans with Gulf War Illness (GWI) often experience a range of debilitating symptoms, including fatigue, chronic pain, depression, anxiety, and cognitive dysfunction. The factors contributing to these symptoms remain poorly understood, but adults with adult growth hormone deficiency (AGHD) experience similar symptoms. Growth hormone replacement therapy has been shown to improve fatigue, chronic pain, mood, cognitive function, and quality of life. Approximately 1 in 3 Veterans diagnosed with GWI also tests positive for AGHD, raising the question of whether growth hormone replacement therapy (GHRT) could be a potential avenue for improving their quality of life. The objective of this research is to conduct a clinical trial to determine whether GHRT can improve body composition, cognitive function, sleep quality, fatigue, and mood in Veterans with GWI and AGHD. Data from this study will also provide important information on the safety of the intervention. This research has the potential to reshape our understanding of GWI and its therapeutic management. If GHRT proves efficacious, it could prompt widespread screening and treatment for growth hormone deficiency among Gulf War Veterans, potentially ameliorating their symptoms and enhancing their functional recovery. Furthermore, the findings of this study may influence clinical practice guidelines, facilitating more effective communication and collaboration among Veterans, caregivers, researchers, and healthcare providers. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02229851 -
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
|
Phase 3 | |
| Completed |
NCT01562834 -
Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients
|
Phase 4 | |
| Completed |
NCT01822340 -
Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients
|
Phase 2 | |
| Completed |
NCT01109017 -
Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency
|
N/A | |
| Completed |
NCT01706783 -
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
|
Phase 1 | |
| Completed |
NCT00184730 -
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
|
Phase 3 | |
| Completed |
NCT00519558 -
Growth Hormone Deficiency in Adults (GHDA)
|
Phase 3 | |
| Terminated |
NCT01698944 -
Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency
|
Phase 4 | |
| Completed |
NCT03075644 -
A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
|
Phase 3 | |
| Completed |
NCT02005198 -
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
|
N/A | |
| Terminated |
NCT01909479 -
A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
|
Phase 3 | |
| Completed |
NCT01806298 -
An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)
|
Phase 4 | |
| Completed |
NCT03186495 -
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
|
Phase 1 | |
| Recruiting |
NCT05979480 -
The Effects of Growth Hormone Treatment Discontinuation in Adults on Metabolic Profile, Body Composition and Quality Of Life (GAMBOL Study)
|
||
| Completed |
NCT02526420 -
Versartis International Trial in Adults With Long-Acting Growth Hormone
|
Phase 2 | |
| Completed |
NCT00934063 -
An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®
|
N/A | |
| Completed |
NCT00715689 -
Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083
|
Phase 2 | |
| Completed |
NCT00297713 -
Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety
|
Phase 2 | |
| Completed |
NCT01543880 -
Safety and Efficacy of Long-term Somatropin Treatment in Adults
|
N/A | |
| Completed |
NCT01580605 -
French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin
|